Overview

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or >75% partial remission )after inductive chemotherapy, CCRT is suggested as the definitive therapy, for the tumor is sensitive to chemotherapy. If the primary tumor shrinks a little or progresses after inductive chemotherapy, operation is suggested as the definitive therapy to get a longer survival.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yan
Collaborator:
Shanghai Junshi Bioscience Co., Ltd.